Sergio Di Matteo
Overview
Explore the profile of Sergio Di Matteo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
321
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Colombo G, Droghetti A, Di Matteo S, Ottenjann H, Bruno G
Ther Clin Risk Manag
. 2025 Mar;
21:257-271.
PMID: 40046260
Background: The international scientific literature is systematically analyzed in this review over a period of nearly 10 years with respect to the use of the active hemostat and surgical sealant...
2.
Bruno G, Di Matteo S, Longo C, Stanganelli I, Farnetani F, Borsari S, et al.
Risk Manag Healthc Policy
. 2025 Jan;
18():163-172.
PMID: 39839194
Background: In a recent prospective, multicenter, two-arm randomized controlled trial (RCT), we demonstrated that adjunctive reflectance confocal microscopy (RCM) in routine clinical practice provides clinical benefits, including safe melanoma detection...
3.
Torre E, Di Matteo S, Bruno G, Martinotti C, Bottaro L, Colombo G
Clinicoecon Outcomes Res
. 2024 Nov;
16:799-811.
PMID: 39525695
Background: Icodec, once-weekly basal insulin, aims to simplify therapy management by reducing injection frequency for diabetic patients. The efficacy and safety of icodec were evaluated in the ONWARDS clinical development...
4.
Torre E, Di Matteo S, Martinotti C, Bruno G, Goglia U, Testino G, et al.
Clinicoecon Outcomes Res
. 2024 Oct;
16:773-784.
PMID: 39469584
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multisystem condition destined to become pandemic in the coming decades. This study aimed at evaluating the economic impact of MASLD in...
5.
Pesce F, Bruno G, Colombo G, Di Matteo S, Maurizi A, Mongelli V, et al.
Clinicoecon Outcomes Res
. 2024 Aug;
16:547-555.
PMID: 39130105
Introduction: The underdiagnosis of chronic kidney disease (CKD) remains a significant public health concern. The Early chroNic kiDney disease pOint of caRe Screening (ENDORSE) project aimed to evaluate the clinical...
6.
Di Matteo S, Freilone R, Bruno G, Notaro R, Moumene S, Martone N, et al.
Clinicoecon Outcomes Res
. 2024 Apr;
16:225-232.
PMID: 38623087
Background: Paroxysmal nocturnal hemoglobinuria is a rare, acquired disease characterized by hemolytic episodes and associated with significant clinical burden. The introduction of C5 inhibitory monoclonal antibodies (C5i) represented a major...
7.
Di Matteo S, Moumene S, Colombo G, De Luca L
G Ital Cardiol (Rome)
. 2024 Jan;
25(1 Suppl 2):e4-e8.
PMID: 38230540
Background: Cardiovascular diseases pose a significant challenge to the society and healthcare systems, with serious implications in terms of mortality and healthcare expenditure. The treatment of cardiovascular diseases, based on...
8.
Bruno G, Valentino M, Brunetti A, Di Matteo S, Begovic I, Croce E, et al.
Pragmat Obs Res
. 2023 May;
14:29-38.
PMID: 37155480
Background: The current flows of the SSN represent the set of interest whose interconnection alone justifies the current study. These flows can be interconnected with other sources, institutional or otherwise,...
9.
Colombo G, Valentino M, Fabi A, Dieci M, Caruggi M, Bruno G, et al.
Ther Clin Risk Manag
. 2023 Apr;
19:301-312.
PMID: 37013197
Background: To date, no study evaluated the cost-effectiveness of palbociclib (PAL) plus fulvestrant (FUL) vs ribociclib (RIB) plus FUL and abemaciclib (ABM) plus FUL in Italy. Cost-effectiveness analysis comparing the...
10.
Torre E, Di Matteo S, Bruno G, Martinotti C, Valentino M, Testino G, et al.
Clinicoecon Outcomes Res
. 2022 Sep;
14:607-618.
PMID: 36127889
Background: Aim of our study is to evaluate the economic impact of NASH among diabetic population in Italy and potential benefits of treatments that can slow the disease progression. Methods:...